Who is sponsoring NCT05647330?

NCT05647330 is sponsored by Henan Cancer Hospital.

What drugs are being tested in NCT05647330?

Interventions in NCT05647330: Hydroxychloroquine Combined With Gemcitabine.

What condition does NCT05647330 study?

NCT05647330 studies Hydroxychloroquine, Gemcitabine, Lung Neoplasms.

Is NCT05647330 still recruiting?

NCT05647330 is currently status unknown. Last updated 12 December 2022.

Last reviewed 2022-12-12 · How we verify

NCT05647330

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer

Status unknown Phase 2 Last updated 12 December 2022

What this trial tests

Phase 2 trial testing Hydroxychloroquine Combined With Gemcitabine in Hydroxychloroquine in 55 participants. Status unknown.

Timeline

15 December 2022

Primary endpoint
1 October 2024

1 October 2025

Quick facts

Lead sponsor	Henan Cancer Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	55
Start date	15 December 2022
Primary completion	1 October 2024
Estimated completion	1 October 2025

Drugs / interventions tested

Hydroxychloroquine Combined With Gemcitabine — full drug profile →

Conditions studied

Hydroxychloroquine — all drugs for Hydroxychloroquine →
Gemcitabine — all drugs for Gemcitabine →
Lung Neoplasms — all drugs for Lung Neoplasms →

Sponsor

Henan Cancer Hospital

Who can join

Adults 18 to 70, any sex, with Hydroxychloroquine or Gemcitabine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the efficacy and safety of hydroxychloroquine (600mgBID) combined with gemcitabine (1000mg/m2,d1,8) in the third-line and above treatment of advanced NSCLC.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Targeted Therapies and Pharmacologic Advances in Mucous Membrane Pemphigoid: A Comprehensive Review.
Busol VN, Kudryashov NV. · · 2025 · PMID 41236290 · DOI 10.5826/dpc.1504a5749

Verify or expand the search:

Other Henan Cancer Hospital trials

Trials by the same sponsor.

NCT07442890 — A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Ro · NA · not yet recruiting
NCT07472621 — Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma · not yet recruiting
NCT07459608 — Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma · Phase 2 · not yet recruiting
NCT07400575 — Anlotinib in Cross-line Treatment of NSCLC and SCLC · not yet recruiting
NCT07332221 — Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05647330 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Henan Cancer Hospital
Last refreshed: 12 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05647330.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing